Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: Results of the Study of Health in Pomerania (SHIP)

Friedrich, Nele; Alte, Dietrich; Völzke, Henry; Spilcke-Liss, Elisabeth; Lüdemann, Jan; Lerch, Markus M.; Kohlmann, Thomas; Nauck, Matthias; Wallaschofski, Henri

doi:10.1016/j.ghir.2007.09.005

Cited by 72 publications

(63 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 These reference values were assayed with the same method as described above. On the basis of quantile regression and the resulting genderand age-specific reference ranges, 30 the highest 2.5% was considered to be 'high', whereas the lowest 2.5% was considered to be 'low'.…”

Section: Methodsmentioning

confidence: 99%

“…Given the considerable age dependence of IGF-I levels, we have compiled reference values for clinical purposes derived from healthy SHIP participants. 30 Odds ratio of all SHIP participants homozygous for the rs9926289 A allele to be in the 'low' IGF-I category amounted to 1.6 and 2.0 before and after adjustments for age, gender and IGFBP3 (Table 2b). For subjects younger than 55 years of age, homozygous carriers of the risk allele had more than twice the odds of belonging to the 'low' IGF-I level group (Table 2b).…”

Section: Igf-i May Link Fto Risk Variants and Increased Bmi D Rosskopmentioning

confidence: 99%

See 1 more Smart Citation

The growth hormone—IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania

Rosskopf

Schwahn²,

Neumann

et al. 2010

Int J Obes

View full text Add to dashboard Cite

Context: Risk alleles of the fat mass-and obesity-associated gene (FTO) are related not only to increased body mass index (BMI) values but also to mortality. It was speculated that cellular effects of the FTO gene affect most organs, especially their ability to maintain or regenerate proper function when afflicted by various diseases. FTO is highly expressed in the hypothalamus and also in the pituitary gland. The decrease in growth hormone (GH) secretion is known to cause a decrease in lean body mass in older subjects. Objective: We hypothesized an association of rs9926289 with insulin-like growth factor (IGF)-I. Design and setting: Cross-sectional data from the Study of Health in Pomerania, a population-based study in the northeastern part of Germany, were used. Participants: For the final analyses, 3882 subjects aged 20-79 years were available. Main outcome measures: Continuous IGF-I, low IGF-I according to clinically meaningful age-and gender-specific reference values, and BMI were used as outcome measures. Results: Over all age groups, a statistically significant relationship between FTO and IGF-I was found. In subjects younger than 55 years of age, homozygous carriers of the FTO risk allele exhibited lower serum IGF-I levels adjusted for 5-year age groups, gender and IGF-I binding protein 3 levels (linear regression, coefficient ± s.e. for FTO AA genotype:À8.6 ± 2.8; P ¼ 0.002). Further adjustments for obesity and diabetes did not suspend this association (coefficient:-7.8; P ¼ 0.005). As expected, the FTO AA genotype effect on BMI was reduced from 0.76 to 0.62 kg m À2 by including IGF-I. No relationship between FTO and IGF-I levels was found in subjects aged 55 years or older (À2.7±2.4; P ¼ 0.260 for FTO AA genotype adjusted for age, gender and IGF-I binding protein 3 levels). Conclusion: We propose that the GHFIGF-I axis is a mediator for the relationship between FTO and BMI.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Igf-i May Link Fto Risk Variants and Increased Bmi D Rosskopmentioning

confidence: 99%

The growth hormone—IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania

Rosskopf

Schwahn²,

Neumann

et al. 2010

Int J Obes

View full text Add to dashboard Cite

show abstract

“…We considered severe GHD when the GH peak was below cut-off limits based upon BMI: for BMI !25 kg/m 2 , a peak of GH %11.5 mg/l; for BMI 25-30 kg/m 2 , a peak of GH %8 mg/l; for BMI O30 kg/m 2 , a peak of GH %4 mg/l (26); IGF1 levels in patients receiving rhGH therapy were between the 50th and 97.5th percentile of normal controls matched for sex and age (27). The diagnosis of other hormone deficiencies (central hypothyroidism or hypogonadism) was based on low pituitary hormone levels with low serum free thyroxine (fT 4 ) or gonadal steroid hormones.…”

Section: Patients and Protocolmentioning

confidence: 99%

Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency

Ceccato

Albiger

Reimondo

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Context: Appropriate glucocorticoid replacement therapy in adrenal insufficiency (AI) is crucial, given the risks of chronic under-or overtreatment, particularly in patients on multiple medications. Salivary sampling allows for non-invasive, stress-free cortisol measurement. Objective: To determine whether salivary cortisol measurement is helpful in assessing the adequacy of glucocorticoid therapy with cortisone acetate (CA) in patients with secondary AI. Design: A prospective cohort study at the Endocrinology Unit of Padua University Hospital. Methods: Six samples of salivary cortisol were collected from 28 patients with secondary AI on CA treatment and from 36 healthy volunteers at fixed times of the day, and used to calculate salivary cortisol levels at each time point and the area under the curve (AUC) across the different sampling times. Results: Salivary cortisol levels were lower in patients than in controls in the morning but no differences were found in the afternoon or at night before resting. Salivary cortisol levels were higher in patients immediately following CA administration. Ten patients showed an AUC above the 97.5th percentile of controls, without clinical signs of hypercortisolism, and salivary cortisol levels 90 min after each dose of CA predict the AUC. All patients had severe GH deficiency and there were no differences in salivary cortisol levels or AUC between patients treated or not with GH. Conclusions: Two salivary cortisol determinations, able to predict the daily AUC, may allow for assessing the adequacy of glucocorticoid replacement therapy in secondary AI and for identifying cases of overor undertreatment.

show abstract

“…The age-related pattern of IGF-1 secretion consists in a decline immediately after birth, followed by an increase until a pubertal peak. Later in life, values decrease continuously (8,14). While techniques for measuring IGF-1 have evolved over the decades (9), immunoassays are still the primary tool used in routine laboratories (7).…”

Section: Introductionmentioning

confidence: 99%

“…Clinicians are therefore often challenged in accurate interpreting IGF-1 concentrations. Laboratories have to face substantial problems with establishing new reference values if assay characteristics change (6,14,16). Therefore, the practical utility of IGF-1 is undermined.…”

Section: Introductionmentioning

confidence: 99%

Serum IGF-1 levels measured by different ELISA assays and IRMA - a comparability study

Stoeva

Aroyo

Emilova

et al. 2015

SSM

View full text Add to dashboard Cite

Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: Results of the Study of Health in Pomerania (SHIP)

Cited by 72 publications

References 35 publications

The growth hormone—IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania

The growth hormone—IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania

Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency

Serum IGF-1 levels measured by different ELISA assays and IRMA - a comparability study

Contact Info

Product

Resources

About